KindlyMD (NASDAQ:NAKA) Trading Down 5% - Should You Sell?

Key Points

• KindlyMD's stock price decreased by 5% during mid-day trading, hitting a low of $1.41 before closing at $1.42 with a significant increase in trading volume.
• Maxim Group has initiated coverage of KindlyMD with a "buy" rating and a target price of $8.00, contributing to the company's overall "Buy" rating and average target price.
• KindlyMD reported a quarterly loss of ($0.34) EPS and revenue of $0.41 million, displaying negative net margins and return on equity metrics.

KindlyMD, Inc. (NASDAQ:NAKA - Get Free Report)'s stock price dropped 5% during mid-day trading on Friday . The company traded as low as $1.41 and last traded at $1.42. Approximately 11,935,607 shares were traded during trading, an increase of 155% from the average daily volume of 4,683,855 shares. The stock had previously closed at $1.49.

Analyst Ratings Changes

Separately, Maxim Group started coverage on KindlyMD in a research note on Wednesday, September 3rd. They issued a "buy" rating and a $8.00 price target on the stock. One research analyst has rated the stock with a Buy rating, Based on data from MarketBeat, the company has an average rating of "Buy" and an average target price of $8.00.

KindlyMD Price Performance

The stock has a market cap of $523.71 million, a price-to-earnings ratio of -1.61 and a beta of 33.96. The company's fifty day moving average price is $8.26.

KindlyMD (NASDAQ:NAKA - Get Free Report) last announced its quarterly earnings results on Tuesday, August 5th. The company reported ($0.34) earnings per share (EPS) for the quarter. The firm had revenue of $0.41 million for the quarter. KindlyMD had a negative net margin of 244.00% and a negative return on equity of 131.09%.

About KindlyMD

Kindly MD, Inc (“KindlyMD” or “Kindly”) is a Utah company formed in 2019. KindlyMD is a healthcare data company, focused on holistic pain management and reducing the impact of the opioid epidemic. KindlyMD offers direct health care to patients integrating prescription medicine and behavioral health services to reduce opioid use in the chronic pain patient population.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.